Correlation Between ZyVersa Therapeutics and NovaBay Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and NovaBay Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and NovaBay Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ZyVersa Therapeutics and NovaBay Pharmaceuticals, you can compare the effects of market volatilities on ZyVersa Therapeutics and NovaBay Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of NovaBay Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and NovaBay Pharmaceuticals.

Diversification Opportunities for ZyVersa Therapeutics and NovaBay Pharmaceuticals

-0.59
  Correlation Coefficient

Excellent diversification

The 3 months correlation between ZyVersa and NovaBay is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and NovaBay Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NovaBay Pharmaceuticals and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with NovaBay Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NovaBay Pharmaceuticals has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and NovaBay Pharmaceuticals go up and down completely randomly.

Pair Corralation between ZyVersa Therapeutics and NovaBay Pharmaceuticals

Given the investment horizon of 90 days ZyVersa Therapeutics is expected to generate 0.92 times more return on investment than NovaBay Pharmaceuticals. However, ZyVersa Therapeutics is 1.09 times less risky than NovaBay Pharmaceuticals. It trades about -0.1 of its potential returns per unit of risk. NovaBay Pharmaceuticals is currently generating about -0.1 per unit of risk. If you would invest  494.00  in ZyVersa Therapeutics on August 29, 2024 and sell it today you would lose (387.00) from holding ZyVersa Therapeutics or give up 78.34% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

ZyVersa Therapeutics  vs.  NovaBay Pharmaceuticals

 Performance 
       Timeline  
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
NovaBay Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in NovaBay Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental drivers, NovaBay Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

ZyVersa Therapeutics and NovaBay Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ZyVersa Therapeutics and NovaBay Pharmaceuticals

The main advantage of trading using opposite ZyVersa Therapeutics and NovaBay Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, NovaBay Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NovaBay Pharmaceuticals will offset losses from the drop in NovaBay Pharmaceuticals' long position.
The idea behind ZyVersa Therapeutics and NovaBay Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments